The Leukemia Research Foundation (LRF) is pleased to announce the distribution of $800,000 in funding for blood cancer research at institutions all over the United States and around the world. The individual, one-year grants of up to $100,000 provide support for projects aimed at gaining a better understanding blood cancers, as well as bolster the careers of “New Investigators”, – a key niche of innovative scientists who are beginning to establish their own laboratories and are no longer under the tutelage of a senior scientist mentor. The funding enables New Investigators to act on their ideas, and try new procedures and experiments that will lead to significant breakthroughs.
The list of grantees and projects funded is as follows:
17th Annual David Sachs Memorial Grant
Ido Bachelet, PhD – Bar Ilan University, Israel
Targeted Leukemia Therapy by Logic-guided DNA Nanorobots
2nd Annual ITxM Blood Science Foundation Research Grant
Z. Basar Bilgicer, PhD – University of Notre Dame, Indiana
Designer Nanoparticles to Treat Multiple Myeloma and Its Microenvironment
15th Annual Ann Sherman Memorial Grant
Katia Basso, PhD – Columbia University, New York
The miRNA-mediated program of BCL6 in Germinal Center B Cells
17th Annual Charles A. Sachs Memorial Grant
Andrew Holland, Ph.D. – Johns Hopkins University School of Medicine, Maryland
Investigating the Contribution of Centrosome Amplification in Hematological Malignancies
8th Annual George Richard Memorial Grant
Sebastien Malinge, Ph.D. – INSERM U985, Institut Gustave Roussy, France
Predisposing Role of Trisomy 21 in Down Syndrome-associated Acute Lymphoid Leukemia
Inaugural Genentech Research Grant
Adam Mead, MA, BM, Bch, MRCP, MRCPath, PhD - University of Oxford, United Kingdom
Exploring Stem Cell Heterogeneity in the Myeloproliferative Disorders
Suzanne Dreebin Wilensky Memorial Grant
Ann Mullally, MD – Harvard University, Brigham and Women's Hospital, Massachusetts
Determining the Impact of TET2 Loss-of-function Mutations on Hematopoietic Stem Cell Clonal Dynamics and on Susceptibility to Hypomethylating Agents in Myeloid Malignancies
Inaugural Tellabs Foundation Research Grant
Johannes Zakrzewski, MD – Memorial Sloan Kettering Cancer Center, New York
A Novel Therapy for Graft Versus Host Disease Without Compromising Tumor Immunity
“The primary purpose of the LRF is to fund research into the causes of and cures for blood cancers, through the Hollis Brownstein Research Grants Program,” said LRF Executive Director Kevin Radelet.
Dozens of proposals from institutions around the world were received by the LRF. The proposals were organized by specialty then matched to the expertise of the Foundation’s Medical Advisory Board (MAB) by Board Chairperson Patrick J. Stiff, M.D., the Coleman Professor of Oncology and Director of the Cardinal Bernardin Cancer Center at Loyola University Medical Center in Maywood, Ill.
“As one can imagine, with federal funding sources for novel approaches to human cancers drying up, there is keen competition for such funding,” said Dr. Stiff. “This year in fact, the LRF saw a 40% increase over last year in applications and many were truly outstanding. These funds will go to a peer-reviewed, outstanding grant that could very well start the successful career of a new investigator who will make a breakthrough for our patients sometime during his/her career.”
Each proposal was thoroughly evaluated and scored using the same scoring system adhered to by the National Institutes of Health. The full MAB membership, senior scientists from every area of hematologic malignancy research, discussed each project in person that scored in the top half of the preliminary critique. Final recommendations were forwarded to the LRF for funding.
For more information about the Leukemia Research Foundation, the newly-funded research projects and past recipients, visit http://www.allbloodcancers.org/hollis-brownstein-research-grants or call 847-424-0600.